2023-07-25 12:17:00
Reserved for subscribers
Antibodies targeting amyloid proteins confirm their relative success. Cautious, neurologists see it as a change of era in the management of the disease.
By Heloise Rambert
© Andrew Brookes/Image Source via AFP
Published on
Lhe good news in Alzheimer’s disease is not legion. Here’s one: following years of unsuccessful efforts in pharmaceutical research, an international team has just announced a new success. A drug developed by Eli Lilly might be authorized in the United States and Europe, following the publication of a large clinical trial.
The results, published in the prestigious journal Jama, confirm the ability of the treatment, donanemab, to slow the progression of the early disease. The clinical trial was conducted in 8 countries on more than 1,700 people aged 60 to 85 who had not yet reached an advanced stage of the disease.
This new drug belongs to a therapeutic class which is not so new: monoclonal antibodies…
1690567057
#promise #therapeutic #era